Table 1 Demographics of TransATAC and POLAR cohorts
From: Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
| Â | TransATAC | POLAR | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
POLAR RMH | POLAR LUH | Total POLAR (RMH + LUH) | ||||||||||
Patient group | Training | Validation | Total | Cases | Controls | Total | Cases | Controls | Total | Cases | Controls | Total |
Number of patients | 634 | 314 | 948 | 114 | 105 | 219 | 133 | 70 | 203 | 247 | 175 | 422 |
Age at diagnosis, yearsa | ||||||||||||
 Mean, years | 64 | 65 | 65 | 56 | 58 | 57 | 62 | 60 | 61 | 59 | 58 | 59 |
 Median, years | 64 | 64 | 64 | 54 | 58 | 56 | 61 | 58 | 61 | 58 | 58 | 58 |
 Range, years | 48–89 | 47–86 | 47–89 | 29–93 | 28–88 | 28–93 | 35–100 | 35–87 | 35–100 | 29–100 | 28–88 | 28–100 |
Tumour size | ||||||||||||
  < 2 cm | 427 (67%) | 207 (66%) | 634 (67%) | 40 (35%) | 43 (41%) | 83 (38%) | 40 (30%) | 27 (39%) | 67 (33%) | 80 (32%) | 70 (40%) | 150 (36%) |
 2–5 cm | 194 (31%) | 101 (32%) | 295 (31%) | 63 (55%) | 54 (51%) | 117 (53%) | 89 (67%) | 40 (57%) | 129 (64%) | 152 (62%) | 94 (54%) | 246 (58%) |
  > 5 cm | 13 (2%) | 6 (2%) | 19 (2%) | 11 (10%) | 8 (8%) | 19 (9%) | 4 (3%) | 3 (4%) | 7 (3%) | 15 (6%) | 11 (6%) | 26 (6%) |
Grade | ||||||||||||
 1 | 177 (28%) | 88 (28%) | 265 (28%) | 12 (11%) | 14 (13%) | 26 (12%) | 9 (7%) | 11 (16%) | 20 (10%) | 21 (9%) | 25 (14%) | 46 (11%) |
 2 | 368 (58%) | 169 (54%) | 537 (57%) | 48 (42%) | 52 (50%) | 100 (46%) | 72 (54%) | 35 (50%) | 107 (53%) | 120 (49%) | 87 (50%) | 207 (49%) |
 3 | 89 (14%) | 57 (18%) | 146 (15%) | 54 (47%) | 39 (37%) | 93 (42%) | 52 (39%) | 24 (34%) | 76 (37%) | 106 (43%) | 63 (36%) | 169 (40%) |
Histological subtype | ||||||||||||
 IDC | 492 (78%) | 230 (73%) | 722 (76%) | 80 (70%) | 75 (71%) | 155 (71%) | 104 (78%) | 55 (79%) | 159 (78%) | 184 (74%) | 130 (74%) | 314 (74%) |
 ILC | 86 (14%) | 60 (19%) | 146 (15%) | 22 (19%) | 18 (17%) | 40 (18%) | 27 (20%) | 15 (21%) | 42 (21%) | 49 (20%) | 33 (19%) | 82 (19%) |
 Other | 56 (9%) | 24 (8%) | 80 (8%) | 12 (11%) | 12 (11%) | 24 (11%) | 2 (2%) | 0 (0%) | 2 (1%) | 14 (6%) | 12 (7%) | 26 (6%) |
Nodal status | ||||||||||||
 Node negative | 441 (70%) | 224 (71%) | 665 (70%) | 60 (53%) | 56 (53%) | 116 (53%) | 42 (32%) | 29 (41%) | 71 (35%) | 102 (41%) | 85 (49%) | 187 (44%) |
 1–3 positive nodes | 136 (22%) | 63 (20%) | 199 (21%) | 25 (22%) | 34 (32%) | 59 (27%) | 54 (41%) | 31 (44%) | 85 (42%) | 79 (32%) | 65 (37%) | 144 (34%) |
 4 or more nodes | 57 (9%) | 27 (9%) | 84 (9%) | 29 (25%) | 15 (14%) | 44 (20%) | 37 (28%) | 10 (14%) | 47 (23%) | 66 (27%) | 25 (14%) | 91 (22%) |
PgR | ||||||||||||
 Negative | 114 (18%) | 46 (15%) | 160 (17%) | 5 (4%) | 7 (7%) | 12 (5%) | 25 (19%) | 9 (13%) | 34 (17%) | 30 (%) | 16 (%) | 46 (11%) |
 Positive | 513 (81%) | 268 (85%) | 781 (82%) | 20 (18%) | 23 (22%) | 43 (20%) | 102 (77%) | 56 (80%) | 158 (78%) | 122 (%) | 79 (%) | 201 (48%) |
 Unknown | 7 (1%) | – | 7 (1%) | 89 (78%) | 75 (71%) | 164 (75%) | 6 (5%) | 5 (7%) | 11 (5%) | 95 (%) | 80 (%) | 175 (41%) |
NPI categorya | ||||||||||||
  ≤ 3.4 | 298 (47%) | 140 (45%) | 438 (46%) | 25 (22%) | 26 (25%) | 51 (23%) | 15 (11%) | 13 (19%) | 28 (14%) | 40 (16%) | 39 (22%) | 79 (19%) |
 3.4–5.4 | 281 (44%) | 147 (47%) | 428 (45%) | 49 (43%) | 50 (48%) | 99 (45%) | 77 (58%) | 42 (60%) | 119 (59%) | 126 (51%) | 92 (53%) | 218 (52%) |
  > 5.4 | 55 (9%) | 27 (9%) | 82 (9%) | 40 (35%) | 29 (28%) | 69 (32%) | 41 (31%) | 15 (21%) | 56 (28%) | 81 (33%) | 44 (25%) | 125 (30%) |
Endocrine therapya | ||||||||||||
 Tamoxifen only | 301 (47%) | 163 (52%) | 464 (49%) | 80 (70%) | 72 (69%) | 152 (69%) | 96 (72%) | 50 (71%) | 146 (72%) | 176 (71%) | 122 (70%) | 298 (71%) |
 AI | 333 (53%) | 151 (48%) | 484 (51%) | 34 (30%) | 33 (31%) | 67 (31%) | 37 (28%) | 20 (29%) | 57 (28%) | 71 (29%) | 53 (30%) | 124 (29%) |
Chemotherapya | ||||||||||||
 No | 634 (100%) | 314 (100%) | 948 (100%) | 54 (47%) | 49 (47%) | 103 (47%) | 94 (71%) | 55 (79%) | 149 (73%) | 148 (60%) | 104 (59%) | 252 (60%) |
 Yes | 0 | 0 | 0 | 60 (53%) | 56 (53%) | 116 (53%) | 39 (29%) | 15 (21%) | 54 (27%) | 99 (40%) | 71 (41%) | 170 (40%) |